



EVALUATING AND MANAGING ELECTROLYTE DISBALANCES IN THE OUTPATIENT SETTING

CARLOS CORTÉS, MD FASN
NEPHROLOGIST
MARCH 13, 2020



DISCLOSURE

- There are no conflicts of interest



TO BE DISCUSSED

Homeostasis

- Potassium
- Water

Evaluation and Management of Electrolyte Disbalances

- Hyperkalemia
- Hypokalemia
- Hyponatremia
- Hypernatremia


Summary



DISORDERS OF POTASSIUM
BALANCE: HYPERKALEMIA
AND HYPOKALEMIA



POTASSIUM HOMEOSTASIS



Costanzo: Physiology, 4th Edition.
Copyright © 2010 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Increase
Renal K⁺
Excretion

- Aldosterone
- High Na⁺ delivery to distal tubule (diuretics)
- High urine flow (osmotic diuresis)
- High serum K⁺ level
- Delivery bicarbonate to distal tubule

Decrease
Renal K⁺
Excretion

- Absence, or very low aldosterone
- Low Na⁺ delivery to the distal tubule
- Low urine flow
- Low serum K⁺ level
- Kidney Injury

MORTALITY IN DYSKALEMIA






HYPERKALEMIA



MY PATIENT HAS HYPERKALEMIA, WHAT SHOULD I DO?

ECG Changes in Hyperkalemia		
QRS Complex	Approximate Serum Potassium (mmol/l)	ECG Change
P wave T wave	~4	Normal
	6-7	Peaked T waves
	7-8	Flattened P wave, prolonged PR interval, depressed ST segment, peaked T wave
	8-9	Atrial standstill, prolonged QRS duration, further peaking T waves
	>9	Sine wave pattern






CAUSES OF HYPERKALEMIA

Increased potassium release from cells

- Pseudohyperkalemia
 - Fist clenching
 - Tourniquet use
- Metabolic acidosis
- Insulin deficiency, hyperglycemia, and hyperosmolality
- Increased tissue catabolism
- Drugs
- Hyperkalemic Periodic Paralysis

Reduced urinary potassium excretion

- Acute and chronic kidney disease
- Reduced aldosterone secretion or response to aldosterone
- Reduced distal sodium and water delivery
- Drugs



Biff Palmer A Physiologic-Based Approach to the Evaluation of a Patient with Hyperkalemia 2010 AJKD

Medications That Cause HK

MANAGEMENT OF ACUTE HYPERKALEMIA

Medication	Onset	Duration	MoA	Comments
Calcium Gluconate 1g/3min	1-2 min	30-60 min	Protect cardiomyocytes	Does not decrease K ⁺ May have to repeat
RegInsulin 10u IV + Dextrose 50% 50ml (if CBG <250mg/dl)	10-30 min	4-6 hrs	Shifts K ⁺ into cells	Check CBG q30min for 4 hrs, especially if CKD
Inhaled Albuterol, 10-20mg	30 min	2-4 hrs	Shifts K ⁺ into cells	Usual albuterol dose is 1.25mg or 2.5mg
Furosemide	>30 min	2-6 hrs	Kaliuresis	2x Cr rule, use with 0.9%NSS
Hemodialysis	Minutes	Permanent	Removal	May be delayed
Exchangers?	1 hour to days	Permanent?	Remove via GI tract	None approved for acute management

MANAGEMENT OF HYPERKALEMIA IN THE OUTPATIENT SETTING



Diuretics

- Loops (Furosemide, bumetadine, torsemide)
- For patients with CKD, CHF
- Thiazides (Chlorthalidone (preferred), indapamide, hydrochlorothiazide)



Ion-exchange polymers

- Sodium Polystyrene Sulfonate (Kayexalate®)?
- Patiromer (Veltassa®)
- Sodium Zirconium Cyclosilicate (Lokelma®)



Others


- Bicarbonate
- Fludrocortisone
- Limiting potassium intake?
- Discontinue medications?

	 Kayexalate[®] sodium polystyrene sulfonate, USP	 Veltassa[®] (patiromer) for oral suspension	 LOKELMA[™] (sodium zirconium cyclosilicate) 10g for oral suspension
FDA Approval	1958	2015	2018
MoA: Exchange	Na ⁺ for K ⁺	Ca ²⁺ for K ⁺	Na ⁺ /H ⁺ for K ⁺
Na ⁺ Content	1,500mg per 15g	N/A	800mg per 10g
Onset	Hours to days	7 hours	1 – 2.2 hours
Dosing	15-60g 1-4x QD	8.4g QD (max TID)	10g TID (for 48 hrs) then 10g QD
Side Effects	GI (nausea, vomiting, constipation) Severe: GI necrosis, obstruction, perforation	GI (constipation) Hypomagnesemia Hypercalcemia?	GI (diarrhea) Edema
Administration	Liquid or Powder Separate other meds by 3 hours	Mix powder with 90ml of water Separate other meds by 3 – 6 hours	Mix powder with 45ml of water Separate other meds by 2 hours
Cost	\$	\$\$\$	\$\$\$
Storage	Room temperature	Refrigerator (2-8 °C)	Room Temperature
Advantages	Cost and availability	No sodium	Less GI issues, Onset
Disadvantages or concerns	Lack of randomized trials Severe GI AEs High sodium content	Hypomagnesemia Potential for DDIs Must be refrigerated	Availability High sodium content
FDA	No	No	No



HYPOKALEMIA





**MY PATIENT
HAS
HYPOKALEMIA,
WHAT SHOULD
I DO?**

History and
Physical,
medication
review

- GI/skin loss, meds, workplace

CBC, BMP

- Leukocytosis, acid-base, magnesium



Urinary K⁺

- >20mmol/24h – meds, RTA, others
- <20mmol/24h – Poor intake, GI loss

Blood Pressures

- Elevated – plasma aldosterone, renin activity and cortisol
- Low – Bartter, Gitelman, diuretics


MANAGEMENT OF HYPOKALEMIA



>2.5mEq/L				
Oral route preferred	KCL 40mEq Liquid	Tablet – risk of pill esophagitis	Potassium citrate if metabolic acidosis	Meds that increase serum K ⁺




Low salt concentration



DISORDERS OF WATER BALANCE: HYPERNATREMIA AND HYPONATREMIA

High salt concentration




WATER HOMEOSTASIS


Vasopressin (ADH) controls water excretion in collecting system

Osmoreceptors in hypothalamus control vasopressin secretion in response to changes in tonicity

Response to Changes in Serum Osmolality




Plasma Osmolality and Dysnatremias






MORTALITY IN DYSNATREMIAS





HYPERNATREMIA

High salt
concentration





History and physical examination, medication review


Volume Status

Vitals

Spot urine electrolytes and osmolality

Water deprivation test

Diagnostic Approach in Hypernatremia



MY PATIENT HAS
HYPERNATREMIA
, NOW WHAT?

HYPERNATREMIA

The Journal of Emergency Medicine, Vol. 45, No. 2, pp. 228-231, 2013
Copyright © 2013 Elsevier Inc.
Printed in the USA. All rights reserved
0736-4679/\$ - see front matter



<http://dx.doi.org/10.1016/j.jemermed.2012.11.109>

Selected Topics: Critical Care

SURVIVAL OF ACUTE HYPERNATREMIA DUE TO MASSIVE SOY SAUCE INGESTION

David J. Carlberg, MD, Heather A. Borek, MD, Scott A. Syverud, MD, and Christopher P. Holstege, MD

Department of Emergency Medicine, University of Virginia Medical Center, Charlottesville, Virginia

Reprint Address: Heather A. Borek, MD, Department of Emergency Medicine, Division of Medical Toxicology, Einstein Medical Center, 5501 Old York Road, Korman B-6, Philadelphia, PA 19141



□ **Abstract—Background:** Intentional massive sodium chloride ingestions are rare occurrences and are often fatal. **Objectives:** There are a variety of treatment recommendations for hypernatremia, ranging from dialysis to varying rates of correction. We report a case of acute severe hypernatremia corrected with rapid free-water infusions that, to our knowledge, has not been previously reported. **Case Report:** A 19-year-old man presented to the Emer-

associated iatrogenic morbidity and mortality (1,2). Other iatrogenic causes of acute hypernatremia include incorrect dilution of oral rehydration solution, as well as hypertonic intravenous fluids, enemas, gastric lavage, and peritoneal lavage (1,3-5). Acute sodium chloride poisoning in adults generally occurs as a suicide attempt in the setting of mental or emotional disorders (2).



1qt ~ 946ml
15ml Soy Sauce ~ 950mg Na+
He drank 59,850mg of sodium!


DIABETES INSIPIDUS



- Nephrogenic DI:**
- CKD
 - Hypokalemia
 - Hypercalcemia
 - Meds
 - Pregnancy

MANAGEMENT OF HYPERNATREMIA

Management of Hypernatremia



***Free Water Deficit

Change in serum sodium per L of infusate:
 $(\text{Infusate Sodium}) - (\text{Serum Sodium}) / (\text{TBW} + 1)$

Is the rate of correction of hypernatremia associated with clinical outcomes?

Methods and Cohort



Data from Medical Information Mart for Intensive Care-III (MIMIC-III)



Na >155 mmol/L



On admission
N = 122



Hospital-acquired
N = 327



Rapid correction
(>0.5 mmol/L/hr)



Slow correction
(≤0.5 mmol/L/hr)

Findings



Rapid Correction

Slow Correction



30 day mortality
25%

NS

P=0.80

30 day mortality
28%



30 day mortality
44%

NS

P=0.50

30 day mortality
40%



0

cases of cerebral edema, seizures or alteration in consciousness attributable to rapid hypernatremia correction

Conclusions


Rapid correction of hypernatremia was not associated with a higher risk for mortality, seizures, alteration of consciousness and/or cerebral edema in critically ill adults with either admission or hospital-acquired hypernatremia.

Kinsuk Chauhan, Pattharawin Pattharanitima, Niralee Patel, Aine Duffy, et al. **Rate of Correction of Hypernatremia and Health Outcomes in Critically Ill Patients.** CJASN doi: 10.2215/CJN.10640918. Visual Abstract by Michelle Lim, MBChB




HYPONATREMIA


Low salt
concentration




MY PATIENT HAS HYPONATREMIA, WHAT SHOULD I DO?



Diagnostic Approach in Hyponatremia



$Osm = 2 [Na^+] + \underline{Glucose} + \underline{BUN} + \text{Other osmoles}$



HYPONATREMIA TREATMENT

Symptomatic

- Acute (<48 h)
 - Hypertonic Saline (3%) @ 1-2ml/kg/h or a 100mL bolus for resolution of symptoms
- Chronic (>48 h)
 - High risk for complications (CPM)
 - Hypertonic saline (3%) at 1-2ml/kg/hr but not > 8-10mEq/L/24hrs
 - Can add D5W or DDVAP lock
 - If potassium is replaced, this will also increase plasma sodium

Asymptomatic

- Review for reversible causes
- Fluid restriction
- Tolvaptan
- Increased salt intake (salt tablets)
- Oral Urea
- SGLT 2 inhibitors?


OUTPATIENT TREATMENT OF EUVOLEMIC HYPONATREMIA

Treatment of Chronic Asymptomatic Hyponatremia				
Treatment	Mechanism of Action	Dose	Advantages	Limitations
Fluid restriction	Decreases availability of free water	<800ml-1,000ml/day	Effective and inexpensive; not complicated	Noncompliance
Pharmacologic Inhibition of Vasopressin Action				
Lithium	Inhibits kidney's response to vasopressin	900-1,200 mg/day	Unrestricted water intake	Polyuria, narrow therapeutic range, toxicities
Demeclocycline	Inhibits kidney's response to vasopressin	300-600 mg twice daily	Effective; unrestricted water intake	Neurotoxicity, polyuria, photosensitivity, nephrotoxicity
Tolvaptan	Antagonizes vasopressin action	15mg-60mg/day	Addresses underlying mechanisms	Limited clinical experience Very expensive Limited to 1 month of therapy Liver toxicity
Increased Solute (Salt) Intake				
With furosemide	Increases free water clearance	Titrate to optimal dose; coadminister 2-3 g NaCl	Effective	Ototoxicity, K ⁺ depletion
With urea	Osmotic diuresis	30-60 g/day	Effective; unrestricted water intake	Polyuria, unpalatable, gastrointestinal symptoms

SGLT2 INHIBITORS???

Empagliflozin increases plasma sodium levels in patients with the syndrome of inappropriate antidiuresis (SIAD)

METHODS




OUTCOME

Median (IQR) increase
p-sodium in mmol/l:

Empagliflozin 10 (5,10)

Placebo 7 (3,11)



CONCLUSION Empagliflozin in addition to fluid restriction leads to a higher increase in plasma sodium levels compared to placebo in hospitalized patients with SIAD.

doi: 10.1681/ASN.2019090944

SUMMARY

- Overall, the most important clues that will lead you to a diagnosis are in the history, physical exam and medication review
- Any patient with concerning or severe symptoms or severe electrolyte disbalance, send to an ER
- Hyperkalemia
 - Limits use of many beneficial agents, maybe with new binders we can improve outpatient management
- Hypokalemia
 - Urine electrolytes will help distinguish between renal and non renal losses

SUMMARY

- Hyponatremia
 - Most common cause of hyponatremia is loss of hypotonic body fluids with inadequate water replacement because of lack of access or adipsia
 - Oral hydration is preferred method for treatment
- Hypernatremia
 - The most helpful in differential diagnosis is volume status
 - SGLT2 inhibitors may help with chronic SIADH

Thank
you!!!
...





REFERENCES

- Berl, T., Sands, J. Disorders of Water Metabolism. *Comprehensive Clinical Nephrology*, 8, 94-110
- Carlberg, D., Borek, H., et al. Survival of Acute Hypernatremia Due to Massive Soy Sauce Ingestion. *Journal of Emergency Medicine*, 2013-08-01, 45 (2), 228-231
- Chauhan, K., et al. Rate of Correction of Hypernatremia and Health Outcomes in Critically Ill Patients. *CJASN*. May 2019, 14 (5) 656-663
- Christ, M., Bichet, D., Diabetes Insipidus. *Nature Reviews Disease Primers*. Volume 5, Article 54 (2019)
- Collins, A., Pitt, B., et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. *Am J Nephrol* 2017;46:213-221
- Costanzo, L. *Potassium Balance*. Renal Physiology. Chapter 6. *Physiology*, 3rd edition, 245-310
- Gubbi, Sriram & Koch, Christian & Verbalis, Joseph & Hannah-Shmouni, Fady. (2019). DIAGNOSTIC TESTING FOR DIABETES INSIPIDUS
- Kovesdy, C., Lott, E., et al. Hyponatremia, Hypernatremia, and Mortality in Patients With Chronic Kidney Disease With and Without Congestive Heart Failure. *Circulation* February 2012, 125 (5): 677-684
- Palmer, B. A Physiologic-Based Approach to the Evaluation of a Patient with Hyperkalemia 2010 *AJKD*
- Refardt, J., et al A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. *JASN* March 2020, 31 (3) 615-624
- Weiner D., Linas, S., Wingo, C. Disorders of Potassium Metabolism. *Comprehensive Clinical Nephrology*, 9, 111-123